Antithrombin: Facts and new hypotheses

Blood Coagulation and Fibrinolysis

Volumn 9, Issue SUPPL. 3, 1998, Pages

  Risberg, B ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Anti inflammatory response; Antithrombin III deficiency; Disseminated intravascular coagulation; Sepsis

Indexed keywords

ANTITHROMBIN;

ANTIINFLAMMATORY ACTIVITY; ANTITHROMBIN III DEFICIENCY; BLOOD CLOTTING; CONFERENCE PAPER; DISSEMINATED INTRAVASCULAR CLOTTING; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ANIMALS; ANTITHROMBINS; BLOOD VESSELS; DISSEMINATED INTRAVASCULAR COAGULATION; HUMANS; SEPSIS;

EID: 0032448952     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. McKay DG. Disseminated intravascular coagulation. New York: Harper and Row; 1965.
2. Hardaway PM. Syndromes of disseminated intravascular coagulation, with special reference to shock and hemorrhage. Springfield: Charles C.Thomas; 1966.
3. Rodrigues-Erdmann F. Bleeding due to increased intravascular coagulation. Hemorrhagic syndromes caused by consumption of blood-clotting factors (consumption-coagulopathics). N Engl J Med 1965; 273: 1370-1378.
4. Verstraete M, Vermylen C, Vermylen J, Vandenbroucke J. Excessive consumption of blood coagulation components as cause of hemorrhagic diathesis. Am J Med 1965; 38: 899.
5. Furie B, Furie BC. Molecular and cellular biology of blood coagulation. N Engl J Med 1992; 326: 800-806.
6. Emerson TE Jr, Fournel MA, Redens TB, Taylor FB Jr. Efficacy of antithrombin III supplementation in animal models of fulminant Escherichia coli endotoxemia or bacteremia. Am J Med 1989; 87: 27S-33S.
7. Redens TB, Emerson TE Jr. Antithrombin-III treatment limits disseminated intravascular coagulation in endotoxemia. Circ Shock 1989; 28: 49-58.
8. Albert J, Blomqvist H, Gårdlund B, Jakobsson J, Svensson J, Blombäck M. Effect of antithrombin concentrate on haemostatic variables in critically ill patients. Acta Anaesthesial Scand 1992; 36: 745-752.
9. Blauhut B, Necek S, Kramar H, Vinazzer H, Bergmann H. Activity of antithrombin III and effect of heparin on coagulation in shock. Thromb Res 1980; 19: 775-782.
10. Blauhut B, Necek S, Vinazzer H, Bergmann H. Substitution therapy with an antithrombin III concentrate in shock and DIG. Thromb Res 1982; 27: 271-278.
11. Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992; 101: 816-823.
12. Fourrier F, Chopin C, Huart JJ, Runge I, Caron C, Goudemand J. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 1993; 104: 882-888.
13. Inthorn D, Hoffmann JN, Harti WH, Mühlbayer D, Jochum M. Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock 1997; 8: 328-334.
14. Okano K, Kokudo Y, Okajima K, Hossain MA, Ischimura K, Yachida S et al. Protective effects of antithrombin III supplementation on warm ischemia and reperfusion injury in rat liver. World J Surg 1996; 20: 1069-1075.
15. Hisama N, Yamaguchi Y,Okajima K, Uchiba M, Murakami K, Mori K et al. Anticoagulant pretreatment attenuates production of cytokine-induced neutrophil chemoattractant following ischemia-reperfusion of rat liver. Dig Dis Sci 1996; 41: 1481-1486.
16. Uchiba M, Okajima K, Murakami K, Okabe H, Takatsuki K. Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III. Am J Physiol 1996; 270: 921-930.
17. Yamauchi T, Umeda F, Inoguchi T, Nawata H. Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells. Biochem Biophys Res Commun 1989; 163: 1404-1411.
18. Horie S, Ishii H, Kazama M. Heparin-like glycosaminoglycan is a receptor for antithrombin III-dependent but not for thrombin-dependent prostacyclin production in human endothelial cells. Thromb Res 1990; 59: 895-904.
19. Clowes AW, Clowes MM, Au YP, Reidy MA, Belin D. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res 1990; 67: 61-67.
20. Nelken NA, Soifer SJ, O'Keefe J, Vu TK, Charo IF, Coughlin SR. Thrombin receptor expression in normal and atherosclerotic human arteries. J Clin Invest 1992; 90: 1614-1621.
21. Sarembock IJ, Gertz SD, Gimple LW, Owen RM, Powers E, Roberts WC. Effectiveness of recombinant desulphatohirudin in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation 1991; 84: 232-243.
22. Abendschein DR, Recchia D, Meng YY, Oltrona L, Wickline SA, Eisenberg PR. Inhibition of thrombin attenuates stenosis after arterial injury in minipigs. J Am Coll Cardiol 1996; 28: 1849-1855.
23. Fager G. Thrombin and proliferation of vascular smooth muscle cells. Circ Res 1995; 77: 645-650.
24. Ali MN, Mazur W, Kleiman NS, Rodgers GP, Abukhalil JM, French BA, Raizner AE. Inhibition of coronary restenosis by antithrombin III in atherosclerotic swine. Coron Artery Dis 1996; 7: 851-861.
25. Grip L, Biombäck M, Egberg N, Olsson Å, Svane B, Velander M. Antithrombin III supplementation for patients undergoing PTCA for unstable angina pectoris. A controlled randomized double-blind pilot study. Eur Heart J 1997; 18: 443-449.
26. Frebelius S, Isaksson S, Swedenborg J. Thrombin inhibition by antithrombin III on the subendothelium is explained by the isoform AT beta. Arterioscler Thromb Vasc Biol 1996; 16: 1292-1297.